The fight against diabetes is being revolutionized with an innovative approach from Genprex, with its gene therapy candidate, GPX-002. Genprex, a gene therapy company focused on developing therapies for cancer and diabetic patients, has announced its plan to launch a new subsidiary, NewCo, which would solely focus on developing and commercializing GPX-002.
GPX-002 was designed to treat both Type 1 and Type 2 Diabetes. This gene therapy employs an engineered AAV vector to deliver specific genes—Pdx1 and MafA—to the pancreas, aiming at reprogramming cells to produce insulin or rejuvenate stressed beta cells. This treatment hopes to establish more effective and sustainable glucose control.
More specifically, with Type 1 diabetes where the immune system attacks insulin-producing beta cells, this therapy reprograms pancreatic alpha cells to withstand immune attacks and become more functional insulin producers. With Type 2 diabetes where insulin production often falls short, GPX-002 can regenerate and sustain existing pancreatic beta cells so that they are more effective at producing insulin.
Genprex's plan to create a separate company focused entirely on developing their diabetes gene therapies highlights their dedication to developing GPX-002 into a gene therapy for diabetes, transforming how we view, manage, and treat this chronic disease.
Hopefully, this project will provide millions of people with a path to healthier and more stable lives.
Created: Sept 4th, 2024
Citations:
Genprex, Inc. (2024, September 4). Genprex announces plans to launch separate company to focus on the development of gene therapy to treat Type-1 and type-2 diabetes. PR Newswire.
Comments